



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : C07K 5/02, 7/02, 5/06, 5/08, A61K 37/64	A1	(11) International Publication Number: WO 95/00535	(43) International Publication Date: 5 January 1995 (05.01.95)
--	----	---	---

(21) International Application Number: PCT/US94/06497

(22) International Filing Date: 9 June 1994 (09.06.94)

(30) Priority Data: 08/082,274 24 June 1993 (24.06.93) US

(71) Applicant (for all designated States except US): ALKERMES, INCORPORATED [US/US]; 64 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HARBESON, Scott, L. [US/US]; Apartment 5, 203 Pemberton Street, Cambridge, MA 02140 (US). STRAUB, Julie, Ann [US/US]; 16 Plato Terrace, Winchester, MA 01890 (US).

(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02173 (US).

(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**

*With international search report.*

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: OPTICALLY PURE CALPAIN INHIBITOR COMPOUNDS

(57) Abstract

Optically pure  $\alpha$ -ketoamide compounds, and use therefor in treating neurodegenerative pathologies having enhanced Calpain activity, are disclosed. These compounds comprise optically pure  $\alpha$ -ketoamides, and physiologically acceptable salts thereof, wherein the  $\alpha$ -ketoamide contains an amino acid isomer which has an L-configuration about the chiral center which is structurally located in the  $\alpha$  position to the ketone of the  $\alpha$ -ketoamide, and wherein the amide functionality of the  $\alpha$ -ketoamide portion of the compound's molecule is derived from an amine of an amino acid or an amine substituted with a sulfone functionality. The method of treating a human neurodegenerative pathology, having enhanced Calpain activity, with a Calpain inhibitor composition while reducing undesirable inhibition of other cysteine proteases and other side effects associated with the racemic Calpain inhibitor composition includes administering an optically pure L-isomer of an  $\alpha$ -ketoamide compound, wherein the L-isomer is substantially free of its D-isomer. The method of forming an optically pure L- $\alpha$ -ketoamide includes mixing an L- $\beta$ -amino- $\alpha$ -hydroxyamide in a solution containing a free radical catalyst and then mixing an oxydizing agent into said solution under conditions sufficient to form said optically pure L- $\alpha$ -ketoamide.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-51-

CLAIMS

1. A compound represented by the formula:  

$$M-AA^1_x-AA^2-NHCH(R^1)CO-CO-NH-R^2-SO_2-R^3$$
and physiologically acceptable salts thereof, wherein
  - 5 M is H,  $NH_2-CO-$ ,  $NH_2-CS-$ ,  $NH_2-SO_2-$ ,  $R^7-NH-CO-$ ,  $R^7_2N-CO-$ ,  $R^7-NH-CS-$ ,  $R^7_2N-CS-$ ,  $R^7-NH-SO_2-$ ,  $R^7_2N-SO_2-$ ,  $R^7-CO-$ ,  $R^7-CS-$ ,  $R^7-SO_2-$ ,  $R^7-O-CO-$ ,  $R^7-O-CS-$ ,  $R^8N-CO-$ ,  $R^8N-CS-$  or  $R^8N-SO_2-$ ;
  - 10  $R^7$  is a  $C_{1-10}$  alkyl,  $C_{1-10}$  fluoroalkyl,  $C_{1-10}$  alkyl substituted with J,  $C_{1-10}$  fluoroalkyl substituted with J, 1-admantyl, 9-fluoroalkyl, phenyl substituted n times with K, naphthyl substituted n times with K,  $C_{1-10}$  alkyl with an attached phenyl group substituted with K,  $C_{1-10}$  alkyl with two attached phenyl groups substituted with K, 15  $C_{1-10}$  alkyl with an attached phenoxy group, or  $C_{1-10}$  alkyl with an attached phenoxy group substituted with K on the phenoxy group;
  - 20 n is 0, 1, 2 or 3;
  - J is a halogen, hydroxyl, carboxy, cyano, amino, nitro,  $C_{1-10}$  alkyoxy,  $C_{1-10}$  alkamino,  $C_{2-12}$  dialkamino,  $C_{1-10}$  alkoxy-CO- group,  $C_{1-10}$  alkoxy-NH- group,  $C_{1-10}$  alkyl-S- group, or  $C_{1-10}$  alkyl-SO<sub>2</sub>- group;
  - 25 K is a halogen, hydroxyl, carboxy, cyano, amino, nitro,  $C_{1-10}$  alkyl,  $C_{1-10}$  perfluoroalkyl,  $C_{1-10}$  alkamino,  $C_{2-12}$  dialkamine,  $C_{1-10}$  alkoxy-CO- group,  $C_{1-10}$  acyl,  $C_{1-10}$  alkyloxy group,  $C_{1-10}$  alkyl-S- group or  $C_{1-10}$  alkyl-SO<sub>2</sub>- group;
  - 30  $R^8N$  is a  $C_{3-6}$  saturated or unsaturated heterocycle containing at least one nitrogen atom. Said heterocycle can contain Q additional heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur and combinations thereof.

-52-

Further, said heterocycle can be substituted with one or more substituents selected from the group consisting of a hydroxyl, halogen, alkyl, cycloalkyl, aryl, alkoxy, alkoxy carbonyl, alkylthio and amino.

Q is 0, 1 or 2;

AA<sup>1</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L configuration, D configuration or no chirality at the  $\alpha$ -carbon, wherein said amino acid is selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfone, methionine sulfoxide, phenylalanine, tryptophan, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine,  $\beta$ -alanine, norleucine, norvaline,  $\alpha$ -aminobutyric acid,  $\epsilon$ -aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline-2-carboxylic acid, 2-azetidine-carboxylic acid, pipercolinic acid, O-methylserine, O-ethyl-serine, S-methylcysteine, S-ethylcysteine, S-benzyl-cysteine, S-methylcysteine sulfone, S-ethylcysteine sulfone, S-benzyl-cysteine sulfone, cyclohexylalanine, homophenylalanine, p-chloro-phenylalanine, p-nitro-phenylalanine, p-amino-phenylalanine, 4-methoxy-phenylalanine, thienylalanine, pyridylalanine,  $\text{NH}_2$ - $\text{CH}(\text{CH}_2\text{CH}(\text{CH}_2\text{CH}_3)_2)$ -COOH,  $\alpha$ -aminoheptanoic acid,  $\text{NH}_2$ - $\text{CH}(\text{CH}_2$ -1-naphthyl)-COOH,  $\text{NH}_2$ - $\text{CH}(\text{CH}_2$ -2-naphthyl)-COOH,  $\text{NH}_2$ - $\text{CH}(\text{CH}_2$ -cyclohexyl)-COOH,  $\text{NH}_2$ - $\text{CH}(\text{CH}_2$ -cyclopentyl)-COOH,  $\text{NH}_2$ - $\text{CH}(\text{CH}_2$ -cyclobutyl)-COOH,  $\text{NH}_2$ - $\text{CH}(\text{CH}_2$ -cyclopropyl-butyl)-COOH,

-53-

trifluoroleucine or hexafluoroleucine;

X is 0, 1, 2 or 3;

AA<sup>2</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L or D configuration at the  $\alpha$ -carbon, wherein said amino acid residue imparts calpain-specificity to calpain inhibitor molecules;


NHCH(R<sup>1</sup>)CO is a side chain blocked or unblocked amino acid with the L configuration and wherein R<sup>1</sup> is a branched or unbranched C<sub>1-8</sub> alkyl, cycloalkyl or fluoroalkyl;

R<sup>2</sup> is a branched or unbranched, saturated or unsaturated constituent selected from the group consisting of C<sub>1-20</sub> alkyl, C<sub>1-20</sub> cycloalkyl, C<sub>1-20</sub> alkyl with an attached phenyl group which is substituted n times with K, and C<sub>1-20</sub> cycloalkyl with an attached phenyl group which is substituted n times with K, and wherein said constituent can be substituted one or more times with Z;

Z is a hydroxyl, carboxy, alkoxy, alkoxymethoxy, alkanoate, alky; carbamyl, -O-CH<sub>2</sub>-SO<sub>2</sub>-CH<sub>3</sub> group, -OCH<sub>2</sub>CH<sub>2</sub>-O-CH<sub>2</sub>CH<sub>2</sub>-OH group, or -OCH<sub>2</sub>CH<sub>2</sub>-O-CH<sub>2</sub>CH<sub>2</sub>-OCH<sub>3</sub> group; and

R<sup>3</sup> is R<sup>2</sup>, -OH, -OR<sup>2</sup>, NH<sub>2</sub>, NHR<sup>2</sup> or NR<sup>2</sup>R<sup>2</sup>.

2. A compound represented by the formula:



and physiologically acceptable salts thereof, wherein

M is H, NH<sub>2</sub>-CO-, NH<sub>2</sub>-CS-, NH<sub>2</sub>-SO<sub>2</sub>-, R<sup>7</sup>-NH-CO-, R<sup>7</sup><sub>2</sub>N-CO-, R<sup>7</sup>-NH-CS-, R<sup>7</sup><sub>2</sub>N-CS-, R<sup>7</sup>-NH-SO<sub>2</sub>-, R<sup>7</sup><sub>2</sub>N-SO<sub>2</sub>-,

-54-

$R^7$ -CO-,  $R^7$ -CS-,  $R^7$ -SO<sub>2</sub>-,  $R^7$ -O-CO-,  $R^7$ -O-CS-,  $R^8$ N-CO-,  $R^8$ N-CS- or  $R^8$ N-SO<sub>2</sub>-;

5  $R^7$  is a C<sub>1-10</sub> alkyl, C<sub>1-10</sub> fluoroalkyl, C<sub>1-10</sub> alkyl substituted with J, C<sub>1-10</sub> fluoroalkyl substituted with J, 1-admantyl, 9-fluoroalkyl, phenyl substituted n times with K, naphthyl substituted n times with K, C<sub>1-10</sub> alkyl with an attached phenyl group substituted with K, C<sub>1-10</sub> alkyl with two attached phenyl groups substituted with K, 10 C<sub>1-10</sub> alkyl with an attached phenoxy group, or C<sub>1-10</sub> alkyl with an attached phenoxy group substituted with K on the phenoxy group;

n is 0, 1, 2 or 3;

15 J is a halogen, hydroxyl, carboxy, cyano, amino, nitro, C<sub>1-10</sub> alkyoxy, C<sub>1-10</sub> alkamino, C<sub>2-12</sub> dialkamino, C<sub>1-10</sub> alkoxy-CO- group, C<sub>1-10</sub> alkoxy-NH- group, C<sub>1-10</sub> alkyl-S- group, or C<sub>1-10</sub> alkyl-SO<sub>2</sub>- group;

20 K is a halogen, hydroxyl, carboxy, cyano, amino, nitro, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> perfluoroalkyl, C<sub>1-10</sub> alkamino, C<sub>2-12</sub> dialkamine, C<sub>1-10</sub> alkoxy-CO- group, C<sub>1-10</sub> acyl, C<sub>1-10</sub> alkyloxy group, C<sub>1-10</sub> alkyl-S- group or C<sub>1-10</sub> alkyl-SO<sub>2</sub>- group;

25  $R^8$ N is a C<sub>3-6</sub> saturated or unsaturated heterocycle containing at least one nitrogen atom. Said heterocycle can contain Q additional heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur and combinations thereof.

30 Further, said heterocycle can be substituted with one or more substituents selected from the group consisting of a hydroxyl, halogen, alkyl, cycloalkyl, aryl, alkoxy, alkoxycarbonyl, alkylthio and amino.

Q is 0, 1 or 2;

-55-

AA<sup>1</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L configuration, D configuration or no chirality at the  $\alpha$ -carbon, wherein said amino acid is selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfone, methionine sulfoxide, phenylalanine, tryptophan, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine,  $\beta$ -alanine, norleucine, norvaline,  $\alpha$ -aminobutyric acid,  $\epsilon$ -aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline-2-carboxylic acid, 2-azetidine-carboxylic acid, pipercolinic acid, O-methylserine, O-ethyl-serine, S-methylcysteine, S-ethylcysteine, S-benzyl-cysteine, S-methylcysteine sulfone, S-ethylcysteine sulfone, S-benzyl-cysteine sulfone, cyclohexylalanine, homophenylalanine, p-chloro-phenylalanine, p-nitro-phenylalanine, p-amino-phenylalanine, 4-methoxy-phenylalanine, thienylalanine, pyridylalanine, NH<sub>2</sub>-CH(CH<sub>2</sub>CH(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>)-COOH,  $\alpha$ -aminoheptanoic acid, NH<sub>2</sub>-CH(CH<sub>2</sub>-1-naphthyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-2-naphthyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-cyclohexyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-cyclopentyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-cyclobutyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-cyclopropyl-butyl)-COOH, trifluoroleucine or hexafluoroleucine;

X is 0, 1, 2 or 3;

AA<sup>2</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L or D

-56-

configuration at the  $\alpha$ -carbon, wherein said amino acid residue imparts calpain-specificity to calpain inhibitor molecules;


5  $AA^3$  is an amino acid residue of a side chain blocked or unblocked amino acid, with the L configuration at the  $\alpha$ -carbon, wherein said amino acid is selected from the group consisting of alanine,  $\alpha$ -aminobutyric acid, norvaline, 10 valine, norleucine, leucine, phenylalanine, tyrosine, cyclohexylalanine, homophenylalanine, p-chloro-phenylalanine, p-nitro-phenylalanine, p-amino-phenylalanine, thionylalanine, lysine, ornithine, aspartic acid, glutamic acid, serine, 15 threonine, pyridylalanine or 4-methoxy-phenylalanine;

$R^2$  is a branched or unbranched, saturated or unsaturated constituent selected from the group consisting of  $C_{1-20}$  alkyl,  $C_{1-20}$  cycloalkyl,  $C_{1-20}$  20 alkyl with an attached phenyl group which is substituted n times with K, and  $C_{1-20}$  cycloalkyl with an attached phenyl group which is substituted n times with K, and wherein said constituent can be substituted one or more times with Z;

25 Z is a hydroxyl, carboxy, alkoxy, alkoxymethoxy, alkanoate, alky; carbamyl,  $-O-CH_2-SO_2-CH_3$  group,  $-OCH_2CH_2-O-CH_2CH_2-OH$  group, or  $-OCH_2CH_2-O-CH_2CH_2-OCH_3$  group; and

$R^3$  is  $R^2$ ,  $-OH$ ,  $-OR^2$ ,  $NH_2$ ,  $NHR^2$  or  $NR^2R^2$ .

30 3. A compound represented by the formula:



and physiologically acceptable salts thereof, wherein

M is H,  $NH_2-CO-$ ,  $NH_2-CS-$ ,  $NH_2-SO_2-$ ,  $R^7-NH-CO-$ ,  $R^7_2N-CO-$ ,  $R^7-NH-CS-$ ,  $R^7_2N-CS-$ ,  $R^7-NH-SO_2-$ ,  $R^7_2N-SO_2-$ ,



-57-

- $R^7$ -CO-,  $R^7$ -CS-,  $R^7$ -SO<sub>2</sub>-,  $R^7$ -O-CO-,  $R^7$ -O-CS-,  $R^8$ N-CO-,  $R^8$ N-CS- or  $R^8$ N-SO<sub>2</sub>-;  
 $R^7$  is a C<sub>1-10</sub> alkyl, C<sub>1-10</sub> fluoroalkyl, C<sub>1-10</sub> alkyl substituted with J, C<sub>1-10</sub> fluoroalkyl substituted with J, 1-admantyl, 9-fluoroalkyl, phenyl substituted n times with K, naphthyl substituted n times with K, C<sub>1-10</sub> alkyl with an attached phenyl group substituted with K, C<sub>1-10</sub> alkyl with two attached phenyl groups substituted with K, C<sub>1-10</sub> alkyl with an attached phenoxy group, or C<sub>1-10</sub> alkyl with an attached phenoxy group substituted with K on the phenoxy group;  
n is 0, 1, 2 or 3;  
J is a halogen, hydroxyl, carboxy, cyano, amino, nitro, C<sub>1-10</sub> alkoxy, C<sub>1-10</sub> alkamino, C<sub>2-12</sub> dialkamino, C<sub>1-10</sub> alkoxy-CO- group, C<sub>1-10</sub> alkoxy-NH- group, C<sub>1-10</sub> alkyl-S- group, or C<sub>1-10</sub> alkyl-SO<sub>2</sub>- group;  
K is a halogen, hydroxyl, carboxy, cyano, amino, nitro, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> perfluoroalkyl, C<sub>1-10</sub> alkamino, C<sub>2-12</sub> dialkamine, C<sub>1-10</sub> alkoxy-CO- group, C<sub>1-10</sub> acyl, C<sub>1-10</sub> alkyloxy group, C<sub>1-10</sub> alkyl-S- group or C<sub>1-10</sub> alkyl-SO<sub>2</sub>- group;  
 $R^8$ N is a C<sub>3-6</sub> saturated or unsaturated heterocycle containing at least one nitrogen atom. Said heterocycle can contain Q additional heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur and combinations thereof. Further, said heterocycle can be substituted with one or more substituents selected from the group consisting of a hydroxyl, halogen, alkyl, cycloalkyl, aryl, alkoxy, alkoxycarbonyl, alkylthio and amino.  
Q is 0, 1 or 2;

-58-

AA<sup>1</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L configuration, D configuration or no chirality at the  $\alpha$ -carbon, wherein said amino acid is selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfone, methionine sulfoxide, phenylalanine, tryptophan, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine,  $\beta$ -alanine, norleucine, norvaline,  $\alpha$ -aminobutyric acid,  $\epsilon$ -aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline-2-carboxylic acid, 2-azetidine-carboxylic acid, pipercolinic acid, O-methylserine, O-ethyl-serine, S-methylcysteine, S-ethylcysteine, S-benzyl-cysteine, S-methylcysteine sulfone, S-ethylcysteine sulfone, S-benzyl-cysteine sulfone, cyclohexylalanine, homophenylalanine, p-chloro-phenylalanine, p-nitro-phenylalanine, p-amino-phenylalanine, 4-methoxy-phenylalanine, thienylalanine, pyridylalanine, NH<sub>2</sub>-CH(CH<sub>2</sub>CH(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>)-COOH,  $\alpha$ -aminoheptanoic acid, NH<sub>2</sub>-CH(CH<sub>2</sub>-1-naphthyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-2-naphthyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-cyclohexyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-cyclopentyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-cyclobutyl)-COOH, NH<sub>2</sub>-CH(CH<sub>2</sub>-cyclopropyl-butyl)-COOH, trifluoroleucine or hexafluoroleucine;

X is 0, 1, 2 or 3;

AA<sup>2</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L or D configuration at the  $\alpha$ -carbon, wherein said amino acid residue imparts calpain-specificity

-59-

to calpain inhibitor molecules;


NHCH(R<sup>1</sup>)CO is a side chain blocked or unblocked amino acid with the L configuration and wherein R<sup>1</sup> is a branched or unbranched C<sub>1-8</sub> alkyl, cycloalkyl or fluoroalkyl;

AA<sup>4</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L configuration, D configuration or no chirality at the  $\alpha$ -carbon, wherein said amino acid is

selected from the group consisting of glycine,  $\beta$ -alanine, alanine,  $\alpha$ -aminobutyric acid, norvaline, valine, norleucine, leucine, phenylalanine, tyrosine, cyclohexylalanine, homophenylalanine, p-chloro-phenylalanine, p-nitro-phenylalanine, p-amino-phenylalanine, thionylalanine, lysine, ornithine, aspartic acid, glutamic acid, serine, threonine, pyridylalanine or 4-methoxy-phenylalanine; and

R<sup>4</sup> is H, C<sub>1-20</sub> alkyl, aryl, C<sub>1-20</sub> alkyl with an attached phenyl group, or C<sub>1-20</sub> alkyl with an attached phenyl group substituted with K.

4. A compound represented by the formula:



and physiologically acceptable salts thereof, wherein

M is H, NH<sub>2</sub>-CO-, NH<sub>2</sub>-CS-, NH<sub>2</sub>-SO<sub>2</sub>-, R<sup>7</sup>-NH-CO-, R<sup>7</sup><sub>2</sub>N-CO-, R<sup>7</sup>-NH-CS-, R<sup>7</sup><sub>2</sub>N-CS-, R<sup>7</sup>-NH-SO<sub>2</sub>-, R<sup>7</sup><sub>2</sub>N-SO<sub>2</sub>-, R<sup>7</sup>-CO-, R<sup>7</sup>-CS-, R<sup>7</sup>-SO<sub>2</sub>-, R<sup>7</sup>-O-CO-, R<sup>7</sup>-O-CS-, R<sup>8</sup>N-CO-, R<sup>8</sup>N-CS- or R<sup>8</sup>N-SO<sub>2</sub>-;

R<sup>7</sup> is a C<sub>1-10</sub> alkyl, C<sub>1-10</sub> fluoroalkyl, C<sub>1-10</sub> alkyl substituted with J, C<sub>1-10</sub> fluoroalkyl substituted with J, 1-admantyl, 9-fluoroalkyl, phenyl substituted n times with K, naphthyl substituted n times with K, C<sub>1-10</sub> alkyl with an attached phenyl group substituted with K, C<sub>1-10</sub> alkyl with

-60-

- two attached phenyl groups substituted with K, C<sub>1-10</sub> alkyl with an attached phenoxy group, or C<sub>1-10</sub> alkyl with an attached phenoxy group substituted with K on the phenoxy group;
- 5        n        is 0, 1, 2 or 3;
- J        is a halogen, hydroxyl, carboxy, cyano, amino, nitro, C<sub>1-10</sub> alkyoxy, C<sub>1-10</sub> alkamino, C<sub>2-12</sub> dialkamino, C<sub>1-10</sub> alkoxy-CO- group, C<sub>1-10</sub> alkoxy-NH- group, C<sub>1-10</sub> alkyl-S- group, or C<sub>1-10</sub> alkyl-SO<sub>2</sub>- group;
- 10        K        is a halogen, hydroxyl, carboxy, cyano, amino, nitro, C<sub>1-10</sub> alkyl, C<sub>1-10</sub> perfluoroalkyl, C<sub>1-10</sub> alkamino, C<sub>2-12</sub> dialkamine, C<sub>1-10</sub> alkoxy-CO- group, C<sub>1-10</sub> acyl, C<sub>1-10</sub> alkyloxy group, C<sub>1-10</sub> alkyl-S-group or C<sub>1-10</sub> alkyl-SO<sub>2</sub>- group;
- 15        R<sup>n</sup>N        is a C<sub>3-6</sub> saturated or unsaturated heterocycle containing at least one nitrogen atom. Said heterocycle can contain Q additional heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur and combinations thereof.
- 20        Further, said heterocycle can be substituted with one or more substituents selected from the group consisting of a hydroxyl, halogen, alkyl, cycloalkyl, aryl, alkoxy, alkoxycarbonyl, alkylthio and amino;
- 25        Q        is 0, 1 or 2;
- AA<sup>1</sup>        is an amino acid residue of a side chain blocked or unblocked amino acid, with the L configuration, D configuration or no chirality
- 30        at the  $\alpha$ -carbon, wherein said amino acid is selected from the group consisting of alanine, valine, leucine, isoleucine, proline, methionine, methionine sulfone, methionine sulfoxide, phenylalanine, tryptophan, glycine, serine, threonine, cysteine, tyrosine,
- 35

-61-

- asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, phenylglycine,  $\beta$ -alanine, norleucine, norvaline,  $\alpha$ -aminobutyric acid,  $\epsilon$ -aminocaproic acid, citrulline, hydroxyproline, ornithine, homoarginine, sarcosine, indoline-2-carboxylic acid, 2-azetidine-carboxylic acid, pipercolinic acid, O-methylserine, O-ethyl-serine, S-methylcysteine, S-ethylcysteine, S-benzyl-cysteine, S-methylcysteine sulfone, S-ethylcysteine sulfone, S-benzyl-cysteine sulfone, cyclohexylalanine, homophenylalanine, p-chloro-phenylalanine, p-nitro-phenylalanine, p-amino-phenylalanine, 4-methoxy-phenylalanine, thienylalanine, pyridylalanine,  $\text{NH}_2\text{-CH}(\text{CH}_2\text{CH}(\text{CH}_2\text{CH}_3)_2)\text{-COOH}$ ,  $\alpha$ -aminoheptanoic acid,  $\text{NH}_2\text{-CH}(\text{CH}_2\text{-1-naphthyl})\text{-COOH}$ ,  $\text{NH}_2\text{-CH}(\text{CH}_2\text{-2-naphthyl})\text{-COOH}$ ,  $\text{NH}_2\text{-CH}(\text{CH}_2\text{-cyclohexyl})\text{-COOH}$ ,  $\text{NH}_2\text{-CH}(\text{CH}_2\text{-cyclopentyl})\text{-COOH}$ ,  $\text{NH}_2\text{-CH}(\text{CH}_2\text{-cyclobutyl})\text{-COOH}$ ,  $\text{NH}_2\text{-CH}(\text{CH}_2\text{-cyclopropyl-butyl})\text{-COOH}$ , trifluoroleucine or hexafluoroleucine;
- X is 0, 1, 2 or 3;
- AA<sup>2</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L or D configuration at the  $\alpha$ -carbon, wherein said amino acid residue imparts calpain-specificity to calpain inhibitor molecules;
- AA<sup>3</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L configuration at the  $\alpha$ -carbon, wherein said amino acid is selected from the group consisting of alanine,  $\alpha$ -aminobutyric acid, norvaline, valine, norleucine, leucine, phenylalanine, tyrosine, cyclohexylalanine, homophenylalanine, p-chloro-phenylalanine, p-nitro-phenylalanine,

-62-

p-amino-phenylalanine, thionylalanine, lysine, ornithine, aspartic acid, glutamic acid, serine, threonine, pyridylalanine or 4-methoxy-phenylalanine;

- 5        AA<sup>4</sup> is an amino acid residue of a side chain blocked or unblocked amino acid, with the L configuration, D configuration or no chirality at the  $\alpha$ -carbon, wherein said amino acid is selected from the group consisting of glycine,  
10         $\beta$ -alanine, alanine,  $\alpha$ -aminobutyric acid, norvaline, valine, norleucine, leucine, phenylalanine, tyrosine, cyclohexylalanine, homophenylalanine, p-chloro-phenylalanine, p-nitro-phenylalanine, p-amino-phenylalanine,  
15        thionylalanine, lysine, ornithine, aspartic acid, glutamic acid, serine, threonine, pyridylalanine or 4-methoxy-phenylalanine; and  
      R<sup>4</sup> is H, C<sub>1-20</sub> alkyl, aryl, C<sub>1-20</sub> alkyl with an attached phenyl group, or C<sub>1-20</sub> alkyl with an  
20        attached phenyl group substituted with K.

5.        A Calpain inhibitor composition, comprising an optically pure L-isomer of an  $\alpha$ -ketoamide compound, said L-isomer being substantially free of its  
25        D-isomer, for use as a medicament in treating a human neurodegenerative pathology having enhanced Calpain activity.

6.        A method of treating a human neurodegenerative pathology, having enhanced Calpain activity, with a Calpain inhibitor composition, while reducing  
30        inhibition of other catalytic proteases and other side effects associated with the racemic calpain inhibitor composition and other side effects, comprising administering to the individual a quantity